Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck & Co., Inc. : quaterly earnings release

10/22/2020 | 09:15am EST

The company will report its earnings for Q3 2020 on 10/27/2020. Generally, the company reports earnings worse than estimates. In recent months, the 5 analysts from Standard & Poor's consensus have revised their EPS estimates upward.


© MarketScreener.com 2020
All news about MERCK & CO., INC.
12/03GLOBAL MARKETS LIVE: 3M, Amazon, Merck…
12/02MERCK : Announces Sale of its Direct Equity Investment in Moderna
PU
11/30MERCK : to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Confer..
BU
11/27OF MOLECULES & MEDICINE : Dr Maurice Hilleman ("The Father Of Modern Vaccines")
AQ
11/24MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
AQ
11/24CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
11/24MERCK : to Acquire OncoImmune
AQ
11/23GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s la..
11/23MERCK : Correction to Merck to Buy OncoImmune Article
DJ
11/23Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments --..
DJ
More news
Financials (USD)
Sales 2020 48 179 M - -
Net income 2020 12 009 M - -
Net Debt 2020 14 601 M - -
P/E ratio 2020 17,4x
Yield 2020 2,97%
Capitalization 207 B 207 B -
EV / Sales 2020 4,61x
EV / Sales 2021 4,25x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,33 $
Last Close Price 81,94 $
Spread / Highest target 30,6%
Spread / Average Target 17,6%
Spread / Lowest Target 3,73%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-9.91%207 311
JOHNSON & JOHNSON3.02%395 592
ROCHE HOLDING AG-3.74%290 107
PFIZER, INC.8.67%224 226
NOVARTIS AG-11.64%207 247
ABBVIE INC.21.17%189 400